2021年1-4月，我国医药行业规模以上企业数量达到8225家，其中亏损企业数量1949家，亏损面24%，环比下降了2个百分点。医药行业亏损总额106.7亿元，同比下降14.8%。

产业痛点：目前我国医药产业总体在政策导向下面临转型压力，而我国传统医药产 业痛点主要集中于经营模式过于单一，线上监管滞后以及针对供应链管理的不足。 亟需医药产业互联网协同创新，优化信息流。 

经历疫情后的医疗健康产业积极开展多角度产业升级，在用户意识、产业数学信息化与新技术等方面实现快速发展。

2021年1-2月，我国医药行业规模以上企业数量达到8228家，其中亏损企业数量2078家，亏损面25%，环比提高了8个百分点。医药行业亏损总额61.2亿元，同比下降3.3%。

2020 年，新冠疫情席卷全球，对各经济体的生产制造、消费投资、社会治理、民众信心等造成全方位冲击，全球经济陷入“大萧条”以来最严重衰退，预计 2020 年全球经济萎缩 3.5%。我国统筹疫情防控和经济社会发展取得重大成果，经济运行持续稳定恢复，就业民生保障有力，经济社会发展主要目标任务完成情况好于预期，初步核算，2020 年国内生产总值比上年增长2.3%。政策方面，多部委出台疫情防控及配套政策，国家药品集采有序推进，国家医保制度不断完善，医疗监管政策全面趋严，多政策促“互联网+医疗健康”向纵深发展，医保支付结算服务持续优化。

本内容通过分析推动市场发展的宏观背景，展现产业链上下游的发展现状和特征，通过典型厂商作为分析，展现厂商在各细分领域中的竞争优势，并对于未来发展的趋势做出预测。

2021年1-3月，我国医药行业规模以上企业数量达到8226家，其中亏损企业数量2140家，亏损面26%，环比提高了1个百分点。医药行业亏损总额92.9亿元，同比下降13.8%。

Endodontics is the study of science related to soft tissue surrounding the root of a tooth and dental pulp. Endodontics include endodontic retreatment, root canal treatment, dental implants and endodontic surgery. This study comprises products only and not the services. The study estimates the revenue generated from the sales of endodontic consumables. The valuations comprise revenue generated from the adoption of root canal procedures by patients. The study scope focuses on endodontics consumables for dental clinics and hospital and dental clinics. Furthermore, the report excludes revenue generated from post-sale services of endodontic consumables.

Bioadhesives are defined as naturally occurring polymeric materials, which possess adhesive characteristics and can adhere to biological surfaces. This substance includes glues created by using biological intermediates such as starch, cellulose, or gelatin. With the growing popularity of bioadhesives, owing to their environmentfriendly nature, they are preferred over synthetic adhesives. These adhesives find their application in several end-use industries such as wood, packaging & paper, construction, and medical industries.

Erythropoietin is a hormone produced primarily by capillary network of the kidney's renal cortex, with small amounts produced by liver and brain. It stimulates production of red blood cells (RBCs). Erythropoietin (EPO) is a protein generated by red blood cells. It is also known as hematopoietin or hemopoietin. Kidney cells produce and release erythropoietin when blood oxygen levels are extremely low. Erythropoietin drugs are used to treat anemia caused by chronic kidney disease (CKD), cancer, and human immunodeficiency virus (HIV). The report provides market dynamics and trends related to the global erythropoietin drugs market. The study estimates revenue generated from sales of erythropoietin products; however, it excludes total revenue for bio similar products. The valuations comprise revenue generated from erythropoietin products such as epoetinalfa, epoetin-beta, and darbepoetin-alfa.

An ultrasonic sensor works by releasing sound waves at high frequency for humans to hear, and when sound is reflected, it calculates the distance based on the time it took to travel. It is widely used in many applications such as presence detection, stacking height control, robotic sensing, liquid level control, loop control, full detection, through-beam detection for high-speed counting, irregular parts detection for hoppers and feeder bowls, 45° deflection, thread or wire break detection, and contouring using ultrasonic systems.

The non-invasive liquid biopsy technique uses samples such as stool, urine, saliva, and other samples, which are extracted without inserting any medical device into the patient’s body. These samples help healthcare professionals to identify biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating messenger RNA (mRNA), circulating microRNA (miRNA), DNA methylation-based biomarkers, exosomes, and extracellular vesicles (EVs). Extensive research is being conducted worldwide for the discovery and presence of novel biomarkers in these samples, which is expected to support the healthcare continuum to conduct liquid biopsy without penetrating any minimally invasive device into the patient’s body.

Animal model is a non-human species utilized in medical research as it shows related aspects of diseases and disorders that are found in humans. It is used to test the efficacy of the treatment cycle and effectiveness of a drug for specific disease condition. The report provides market dynamics and trends related to the animal model market. The study estimates the revenue generated from the sales of animal model types. The valuations comprise revenue generated from animal model types such as rat, mice, guinea pigs, rabbits, and others.

The report covers the detailed analysis of the trends, future estimations, and a thorough study of the global face mask market on the basis of type, material, nature, and distribution channel. It analyzes government regulations, policies, and patents to provide information on the current market trends and suggests future growth opportunities globally.

The report includes the revenue generated from the sales of vaccines used for the prevention of various animal diseases. Recent advancements and developments in the animal vaccines market have enhanced the efficiency of these drugs. Drivers, restraints, and opportunities are explained in detail to understand the market dynamics. Key strategies adopted by the potential market leaders to facilitate effective planning and decision-making are also discussed.

The global urology care devices and platforms market has the presence of various key medical device companies operating in the market. The major medical device companies operating in the market include Baxter International Inc., Olympus Corporation, Boston Scientific Corporation, Becton, Dickinson and Company, and Medtronic plc. The companies offer a diverse product portfolio, including dialysis devices, lasers and lithotripsy devices, and consumables such as guidewires and catheters, stents, and biopsy devices.

景氣展望：儘管特定抗生素類原料藥因海外治療新冠肺炎重症患者所需而持續具 有顯著需求，而且本土廠商所屬利基型產品可望受惠於歐美國家醫藥供應鏈逐步 進行重組的趨勢，從而有效拓展海外市場，不過受到2020年同期國內下游學名藥 廠商積極拉貨、銷售基期有所墊高，加上領導廠商旭富製藥科技短期無法接單生 產的影響，故估計2021年上半年我國原料藥製造業景氣將呈現成長放緩的局面。 

《前沿技术》聚焦于重点行业、重点产品、重点工艺等的前沿技术研发、突破 性进展和商业化应用，帮助用户及时了解重大前沿技术的研发动向和主要趋势，以及主要企 业的技术优势和最新进展，以更好地把握和判断相关技术和产品所处的发展阶段、主要应用 场景、潜在市场价值和可能存在的风险。

总结：随着医院门诊量、住院等逐步恢复到疫情前，2021年上半年治疗性的产品得到恢复，cxo延续快速 增长趋势，医疗服务恢复明显；医美作为新起的板块，上半年表现亮眼。器械板块的DID领域持续受益于新 冠病毒检测侍续高增长。 

2021 年9 月14 日，国家医保局、财政部发布《关于开展门诊慢特病相 关治疗费用跨省直接结算试点工作的通知》医保办函【2021】4 号，分 别从试点目标、试点范围、试点内容和工作要求4 个部分做了部署，目 标为2021 年底前，每个省（自治区、直辖市，含新疆生产建设兵团） 至少选择一个统筹地区开展门诊慢特病相关治疗费用跨省直接结算试 点，可以提供高血压、糖尿病、恶性肿瘤门诊放化疗、尿毒症透析、器 官移植术后抗排异治疗等五个门诊慢特病相关治疗费用跨省直接结算。 工作要求：2021 年9 月30 日以前将试点地区和试点定点医疗机构名单 报送国家医保局备案，2021 年11 月15 日前提交试点地区门诊慢特病医 保政策和接入申请。